Clinical pharmacology of artemisinin-based combination therapies

被引:107
作者
Aweeka, Francesca T. [1 ]
German, Polina L. [1 ]
机构
[1] Univ Calif San Francisco, Drug Res Unit, San Francisco, CA 94143 USA
关键词
D O I
10.2165/00003088-200847020-00002
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Malaria, a disease transmitted by the female Anopheles mosquito, has had devastating effects on human populations for more than 4000 years. Treatment of the disease with single drugs, such as chloroquine, sulfadoxine/pyrimethamine or mefloquine, has led to the emergence of resistant Plasmodium falciparum parasites that lead to the most severe form of the illness. Artemisinin-based combination therapies are currently recommended by WHO for the treatment of uncomplicated P. falciparum malaria. Artemisinin and semisynthetic derivatives, including artesunate, artemether and dihydroartemisinin, are short-acting antimalarial agents that kill parasites more rapidly than conventional antimalarials, and are active against both the sexual and asexual stages of the parasite cycle. Artemisinin fever clearance time is shortened to 32 hours as compared with 2-3 days with older agents. To delay or prevent emergence of resistance, artemisinins are combined with one of several longer-acting drugs - amodiaquine, mefloquine, sulfadoxine/pyrimethamine or lumefantrine - which permit elimination of the residual malarial parasites. The clinical pharmacology of artemisinin-based combination therapies is highly complex. The short-acting artemisinins and their long-acting counterparts are metabolized and/or inhibit/induce cytochrome P450 enzymes, and may thus participate in drug-drug interactions with multiple drugs on the market. Alterations in antimalarial drug plasma concentrations may lead to either suboptimal efficacy or drug toxicity and may compromise treatment.
引用
收藏
页码:91 / 102
页数:12
相关论文
共 110 条
[1]  
ANSDELL VE, 1976, LANCET, V2, P1257
[2]   Population pharmacokinetic assessment of a new regimen of mefloquine used in combination treatment of uncomplicated falciparum malaria [J].
Ashley, Elizabeth A. ;
Stepniewska, Kasia ;
Lindegardh, Niklas ;
McGready, Rose ;
Hutagalung, Robert ;
Hae, Rae ;
Singhasivanon, Pratap ;
White, Nicholas J. ;
Nosten, Francois .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2006, 50 (07) :2281-2285
[3]   CYP2C8 polymorphisms in Caucasians and their relationship with paclitaxel 6α-hydroxylase activity in human liver microsomes [J].
Bahadur, N ;
Leathart, JBS ;
Mutch, E ;
Steimel-Crespi, D ;
Dunn, SA ;
Gilissen, R ;
Van Houdt, J ;
Hendrickx, J ;
Mannens, G ;
Bohets, H ;
Williams, FM ;
Armstrong, M ;
Crespi, CL ;
Daly, AK .
BIOCHEMICAL PHARMACOLOGY, 2002, 64 (11) :1579-1589
[4]   Artemisinin and its derivatives - An important new class of antimalarial agents [J].
Balint, GA .
PHARMACOLOGY & THERAPEUTICS, 2001, 90 (2-3) :261-265
[5]   PHARMACOKINETICS OF ARTEMETHER AFTER ORAL-ADMINISTRATION TO HEALTHY THAI MALES AND PATIENTS WITH ACUTE, UNCOMPLICATED FALCIPARUM-MALARIA [J].
BANGCHANG, KN ;
KARBWANG, J ;
THOMAS, CG ;
THANAVIBUL, A ;
SUKONTASON, K ;
WARD, SA ;
EDWARDS, G .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1994, 37 (03) :249-253
[6]   Protein binding and α:β anomer ratio of dihydroartemisinin in vivo [J].
Batty, KT ;
Ilett, KF ;
Davis, TME .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2004, 57 (04) :529-533
[7]   Assessment of the effect of malaria infection on hepatic clearance of dihydroartemisinin using rat liver perfusions and microsomes [J].
Batty, KT ;
Ilett, KF ;
Edwards, G ;
Powell, SM ;
Maggs, JL ;
Park, BK ;
Davis, TME .
BRITISH JOURNAL OF PHARMACOLOGY, 1998, 125 (01) :159-167
[8]   Pharmacokinetics of artemisinin and artesunate after oral administration in healthy volunteers [J].
Benakis, A ;
Paris, M ;
Loutan, L ;
Plessas, CT ;
Plessas, ST .
AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 1997, 56 (01) :17-23
[9]   Determination of sulfadoxine in human blood plasma using packed-column supercritical fluid chromatography [J].
Bhoir, SI ;
Bhoir, IC ;
Bhagwat, AM ;
Sundaresan, M .
JOURNAL OF CHROMATOGRAPHY B, 2001, 757 (01) :39-47
[10]   PYRIMETHAMINE TOXICITY [J].
BRIGGS, M ;
BRIGGS, M .
BRITISH MEDICAL JOURNAL, 1974, 1 (5896) :40-40